Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinopathy of Prematurity Clear all

Conditions: Retinopathy of Prematurity
Interventions: Goggles, Ambient Light Reduction; Device · Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Up to 1 Day
Timeline: Started 1995
U.S. locations: 3
States / cities: Buffalo, New York • Dallas, Texas • San Antonio, Texas

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Little Rock, Arkansas • Irvine, California • Los Angeles, California + 20 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-1/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: 40 Weeks to 108 Weeks
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Mobile, Alabama • Greenville, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Retinopathy of Prematurity
Interventions: aflibercept, laser photocoagulation; Drug · Procedure
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • La Jolla, California • Loma Linda, California + 21 more

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: Up to 6 Months
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 8 more

Conditions: Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions: ACULAR, REFRESH TEARS, placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 10 Days to 15 Days
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions: OHB-607; Drug
Lead sponsor: OHB Neonatology Ltd.; Industry
Eligibility: 0 Hours to 24 Hours
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 24
States / cities: Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more

Conditions: Pain During ROP Exam
Interventions: ROP exam with spring loaded retractor, ROP exam with screw retractor; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 23 Weeks to 37 Weeks
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Retinopathy of Prematurity (ROP)
Interventions: Ranibizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Retinopathy of Prematurity
Interventions: Trans-scleral Cryotherapy; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Up to 1 Year
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 2003
U.S. locations: 24
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 20 more

Conditions: Lactation
Interventions: Lutein supplement; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Retinopathy of Prematurity
Interventions: Ranibizumab, Laser therapy; Drug · Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more

Conditions: Anemia of Prematurity
Interventions: Red blood cell transfusion; Procedure
Lead sponsor: McMaster University; Other
Eligibility: Up to 48 Hours
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Albany, New York • Brooklyn, New York

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-I/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 1 Day
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Mobile, Alabama • Irvine, California • Augusta, Georgia + 5 more

Conditions: Infant, Newborn, Disease, Pain, Retinopathy of Prematurity, Eye Diseases
Interventions: phototherapy eye shield; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: Up to 1 Year
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
Interventions: No Intervention; Other
Lead sponsor: Oak Hill Bio Ltd; Industry
Eligibility: 12 Months to 24 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: South Bend, Indiana • Jackson, Mississippi • New Brunswick, New Jersey

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more

Conditions: Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
Interventions: Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection; Device · Other
Lead sponsor: Duke University; Other
Eligibility: 30 Weeks and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 3 Days to 6 Days
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more

Conditions: Retinopathy of Prematurity
Interventions: carotenoids; Dietary Supplement
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Days
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Retinopathy of Prematurity
Interventions: Not listed
Lead sponsor: Pediatrix; Other
Eligibility: Up to 7 Days
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: South Bend, Indiana • Las Vegas, Nevada

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab (Avastin); Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 30 Weeks and older
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Bevacizumab Treatment For Type 1 ROP

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

ROP Screening: Comparison of Pain Using Two Eyelid Retractors

Rainbow Extension Study

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

Dietary Lutein and the Retinopathy of Prematurity

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Premature Infants in Need of Transfusion (PINT)

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity

Eye Shields for Infants After Dilated Exam

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

Analyzing Retinal Microanatomy in ROP

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids

Registry for Severe ROP and Treatment on Visual Outcomes

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)